These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 24757229)

  • 21. Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial.
    Haidar A; Legault L; Messier V; Mitre TM; Leroux C; Rabasa-Lhoret R
    Lancet Diabetes Endocrinol; 2015 Jan; 3(1):17-26. PubMed ID: 25434967
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Insulin delivery and nocturnal glucose control in children and adolescents with type 1 diabetes.
    Tauschmann M; Hovorka R
    Expert Opin Drug Deliv; 2017 Dec; 14(12):1367-1377. PubMed ID: 28819992
    [TBL] [Abstract][Full Text] [Related]  

  • 23. "Let the Algorithm Do the Work": Reduction of Hypoglycemia Using Sensor-Augmented Pump Therapy with Predictive Insulin Suspension (SmartGuard) in Pediatric Type 1 Diabetes Patients.
    Biester T; Kordonouri O; Holder M; Remus K; Kieninger-Baum D; Wadien T; Danne T
    Diabetes Technol Ther; 2017 Mar; 19(3):173-182. PubMed ID: 28099035
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Do high fasting glucose levels suggest nocturnal hypoglycaemia? The Somogyi effect-more fiction than fact?
    Choudhary P; Davies C; Emery CJ; Heller SR
    Diabet Med; 2013 Aug; 30(8):914-7. PubMed ID: 23672623
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Night glucose control with MD-Logic artificial pancreas in home setting: a single blind, randomized crossover trial-interim analysis.
    Nimri R; Muller I; Atlas E; Miller S; Kordonouri O; Bratina N; Tsioli C; Stefanija MA; Danne T; Battelino T; Phillip M
    Pediatr Diabetes; 2014 Mar; 15(2):91-9. PubMed ID: 23944875
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of a portable ambulatory prototype for automated overnight closed-loop insulin delivery in young people with type 1 diabetes.
    Elleri D; Allen JM; Biagioni M; Kumareswaran K; Leelarathna L; Caldwell K; Nodale M; Wilinska ME; Acerini CL; Dunger DB; Hovorka R
    Pediatr Diabetes; 2012 Sep; 13(6):449-53. PubMed ID: 22817340
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Insulin pump therapy with automated insulin suspension in response to hypoglycemia: reduction in nocturnal hypoglycemia in those at greatest risk.
    Choudhary P; Shin J; Wang Y; Evans ML; Hammond PJ; Kerr D; Shaw JA; Pickup JC; Amiel SA
    Diabetes Care; 2011 Sep; 34(9):2023-5. PubMed ID: 21868778
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk for ketonaemia in type 1 diabetes pregnancies with sensor-augmented pump therapy with predictive low glucose suspend compared with low glucose suspend: a crossover RCT.
    Benhalima K; van Nes F; Laenen A; Gillard P; Mathieu C
    Diabetologia; 2021 Dec; 64(12):2725-2730. PubMed ID: 34647140
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The use of an automated, portable glucose control system for overnight glucose control in adolescents and young adults with type 1 diabetes.
    O'Grady MJ; Retterath AJ; Keenan DB; Kurtz N; Cantwell M; Spital G; Kremliovsky MN; Roy A; Davis EA; Jones TW; Ly TT
    Diabetes Care; 2012 Nov; 35(11):2182-7. PubMed ID: 22875230
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outpatient overnight glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or conventional insulin pump therapy in children and adolescents with type 1 diabetes: an open-label, randomised controlled trial.
    Haidar A; Legault L; Matteau-Pelletier L; Messier V; Dallaire M; Ladouceur M; Rabasa-Lhoret R
    Lancet Diabetes Endocrinol; 2015 Aug; 3(8):595-604. PubMed ID: 26066705
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Automated overnight closed-loop glucose control in young children with type 1 diabetes.
    Elleri D; Allen JM; Nodale M; Wilinska ME; Mangat JS; Larsen AM; Acerini CL; Dunger DB; Hovorka R
    Diabetes Technol Ther; 2011 Apr; 13(4):419-24. PubMed ID: 21355719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The "Glucositter" overnight automated closed loop system for type 1 diabetes: a randomized crossover trial.
    Nimri R; Danne T; Kordonouri O; Atlas E; Bratina N; Biester T; Avbelj M; Miller S; Muller I; Phillip M; Battelino T
    Pediatr Diabetes; 2013 May; 14(3):159-67. PubMed ID: 23448393
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MD-Logic overnight type 1 diabetes control in home settings: A multicentre, multinational, single blind randomized trial.
    Nimri R; Bratina N; Kordonouri O; Avbelj Stefanija M; Fath M; Biester T; Muller I; Atlas E; Miller S; Fogel A; Phillip M; Danne T; Battelino T
    Diabetes Obes Metab; 2017 Apr; 19(4):553-561. PubMed ID: 27981804
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive Low-Glucose Suspend Reduces Hypoglycemia in Adults, Adolescents, and Children With Type 1 Diabetes in an At-Home Randomized Crossover Study: Results of the PROLOG Trial.
    Forlenza GP; Li Z; Buckingham BA; Pinsker JE; Cengiz E; Wadwa RP; Ekhlaspour L; Church MM; Weinzimer SA; Jost E; Marcal T; Andre C; Carria L; Swanson V; Lum JW; Kollman C; Woodall W; Beck RW
    Diabetes Care; 2018 Oct; 41(10):2155-2161. PubMed ID: 30089663
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DREAM5: An open-label, randomized, cross-over study to evaluate the safety and efficacy of day and night closed-loop control by comparing the MD-Logic automated insulin delivery system to sensor augmented pump therapy in patients with type 1 diabetes at home.
    Biester T; Nir J; Remus K; Farfel A; Muller I; Biester S; Atlas E; Dovc K; Bratina N; Kordonouri O; Battelino T; Philip M; Danne T; Nimri R
    Diabetes Obes Metab; 2019 Apr; 21(4):822-828. PubMed ID: 30478937
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Feasibility of overnight closed-loop control based on hourly blood glucose measurements.
    Patte C; Pleus S; Galley P; Weinert S; Haug C; Freckmann G
    J Diabetes Sci Technol; 2012 Jul; 6(4):902-9. PubMed ID: 22920817
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of Automated Insulin Management Features of the MiniMed
    Zhong A; Choudhary P; McMahon C; Agrawal P; Welsh JB; Cordero TL; Kaufman FR
    Diabetes Technol Ther; 2016 Oct; 18(10):657-663. PubMed ID: 27672710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improved Glycemic Outcomes With Medtronic MiniMed Advanced Hybrid Closed-Loop Delivery: Results From a Randomized Crossover Trial Comparing Automated Insulin Delivery With Predictive Low Glucose Suspend in People With Type 1 Diabetes.
    Collyns OJ; Meier RA; Betts ZL; Chan DSH; Frampton C; Frewen CM; Hewapathirana NM; Jones SD; Roy A; Grosman B; Kurtz N; Shin J; Vigersky RA; Wheeler BJ; de Bock MI
    Diabetes Care; 2021 Apr; 44(4):969-975. PubMed ID: 33579715
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Day-and-Night Closed-Loop Insulin Delivery in a Broad Population of Pregnant Women With Type 1 Diabetes: A Randomized Controlled Crossover Trial.
    Stewart ZA; Wilinska ME; Hartnell S; O'Neil LK; Rayman G; Scott EM; Barnard K; Farrington C; Hovorka R; Murphy HR
    Diabetes Care; 2018 Jul; 41(7):1391-1399. PubMed ID: 29535135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of a Predictive Low-Glucose Management System In-Clinic.
    Buckingham BA; Bailey TS; Christiansen M; Garg S; Weinzimer S; Bode B; Anderson SM; Brazg R; Ly TT; Kaufman FR
    Diabetes Technol Ther; 2017 May; 19(5):288-292. PubMed ID: 28221823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.